Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Report this content

Optomed Plc Stock Exchange Release 2 July 2024 at 10.45, Helsinki

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from Sp Rahastoyhtiö Oy (“Notifier”). According to the notification, the total holdings in Optomed shares and votes held the investment funds of Sp-Rahastoyhtiö (Säästöpankki Pienyhtiöt, Säästöpankki Kotimaaa) is 6.51 per cent of all of the registered shares in Optomed on 1 July 2024.

 

The total number of the Company’s registered shares amounts to 19,630,397 shares. Each share entitles to one vote.

 

The total position of Notifier subject to the notification:

 

 

% of shares and voting rights (total of A)

% of shares and voting rights through financial instruments (total of B)

Total of both in % (A+B)

Total number of shares and voting rights of issuer

Resulting situation on the date on which threshold was crossed or reached

6.51 %

6.51 %

 

 

 

19 630 397

Position of previous notification (if applicable)

 

 

 

 

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

 

A: Shares and voting rights

 

Class/type of shares

 

ISIN code

Number of shares and voting rights

% of shares and voting rights

Direct
(SMA 9:5)

Indirect
(SMA 9:6 and 9:7)

Direct
(SMA 9:5)

Indirect
(SMA 9:6 and 9:7)

FI4000410881

1 278 107

 

6.51%

 

SUBTOTAL A

1 278 107

6.51 %

 

 

 

Further enquiries

Sakari Knuutti, CFO, Optomed Plc, sakari.knuutti@optomed.com

 

 

Optomed in Brief 

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye diseases, such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.

www.optomed.com

 

Subscribe